Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07225556

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Overweight Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Lilly Centre for Clinical Pharmacology, Singapore

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant must be 21 for Singapore site
  • Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
  • Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent [%] body weight change)

Exclusion criteria

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
  • Is an individual of childbearing potential (IOCBP)

Treatment and study plan

LY4167586

Drug

Administered SC

Placebo

Drug

Administered SC

Primary outcomes

  1. Number and Incidence of Serious Adverse Events (SAEs)

    Time frame: Baseline to study completion (up to 29 weeks)

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax)

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)

    PK: Cmax of LY4167586

  2. PK: Time of Maximum Drug Concentration (tmax)

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)

    PK: tmax of LY4167586

  3. PK: Area Under the Concentration Versus Time Curve (AUC)

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)

    PK: AUC of LY4167586

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

A Phase 1, Randomized, Placebo-Controlled, Single Ascending Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Nov 6, 2025
Registry last updated
Jul 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.